• For certain indications, the Moderna COVID‑19 Vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by the FDA, under an Emergency Use Authorization (EUA), to prevent Coronavirus Disease 2019 (COVID‑19) in individuals 18 years of age and older. There are two presentations/formulations of the Moderna COVID‑19 Vaccine authorized for use.

  • The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the COVID‑19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner.

See below for Moderna COVID‑19 Vaccine authorized uses.

Sign up to receive updates from Moderna

Current Clinical Trials

Here are some of the clinical trial programs that are currently investigating Moderna COVID-19 Vaccine.

Independent study: Second Booster Dose

This independent study is an ongoing Phase 3, non-randomized, parallel assignment, open-label study to test the effect of a 4th dose by comparing the immune response before and after the 4th dose given to 150-200 volunteers with various control groups.

Study 2: Booster Dose

Study 2 is an ongoing Phase 2, randomized, observer-blind, placebo-controlled, dose-confirmation study to evaluate the safety, reactogenicity, and immunogenicity of the Moderna COVID-19 Vaccine in participants 18 years of age and older.

Phase 2 Trial, Study P201 (NCT04405076)

Study 1: Primary Series

Study 1 is an ongoing Phase 3 randomized, placebo-controlled, observer-blind clinical trial to evaluate the efficacy, safety, and immunogenicity of the Moderna COVID-19 Vaccine in participants 18 years of age and older in the United States.

Other Primary Series Studies

Phase 1 Trial, Study P101 (NCT04283461)